Literature DB >> 31607573

Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

Jun-Yuan Zheng1, Shie-Shian Huang2, Shu-Huan Huang3, Jung-Jr Ye4.   

Abstract

OBJECTIVES: To investigate clinical and microbiological response, and 30-day mortality of pneumonia involving multidrug-resistant (MDR) Acinetobacter calcoaceticus-Acinetobacter baumannii (Acb) complex treated with colistin, and identify associated factors of these outcomes.
METHODS: A retrospective study of 183 adult patients with colistin treatment for at least 7 days between January 2014 and October 2017.
RESULTS: The mean age was 76.8 years, and mean Acute Physiology and Chronic Health Evaluation II score was 17.7. Eighteen (9.8%) and 128 (69.9%) patients had intravenous (IV) colistin alone and inhaled (IH) colistin alone, respectively. Thirty-seven patients had both IV and IH colistin, including 5 (2.7%) with concurrent, and 32 (17.5%) with non-concurrent use of IV and IH colistin. The 30-day mortality rate was 19.1% and 131 (71.6%) patients had clinical response. In the 175 patients with available data, 126 (72%) had microbiological eradication. The multivariate analyses revealed that IH colistin alone was an independent predictor for 30-day survival, clinical response, and microbiological eradication, and IV colistin alone was an independent predictor for clinical failure. Patients with IV colistin alone had a significantly higher nephrotoxicity rate than IH colistin alone (37.5% vs 6.1%, P = 0.001). Sub-group analysis of 52 patients with IV colistin for ≧ 4 days revealed that 14 (26.9%) patients had inappropriate dose, and inappropriate dose was an independent predictor for 30-day mortality.
CONCLUSIONS: IH colistin provided good outcomes with few side effects, and appropriate dosing of IV colistin was important to avoid excess mortality.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Acinetobacter; Colistin; Pneumonia; Resistance

Mesh:

Substances:

Year:  2019        PMID: 31607573     DOI: 10.1016/j.jmii.2019.08.007

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  3 in total

1.  Successful treatment of Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime/avibactam and aztreonam.

Authors:  Ana Pelaez Bejarano; Raquel Sánchez-Del Moral; Olalla Montero-Pérez; Francisco Javier Martínez-Marcos
Journal:  Eur J Hosp Pharm       Date:  2021-10-29

Review 2.  Systematic review and meta-analysis of the proportion and associated mortality of polymicrobial (vs monomicrobial) pulmonary and bloodstream infections by Acinetobacter baumannii complex.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis
Journal:  Infection       Date:  2021-07-14       Impact factor: 3.553

3.  Co-isolates of Acinetobacter baumannii complex in polymicrobial infections: a meta-analysis.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Evangelos I Kritsotakis
Journal:  Access Microbiol       Date:  2022-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.